CorMedix, Inc. CRMD 深 滬
等待開盤 10-23 09:30:00 美东时间
11.20
-0.450
-3.86%
華盛通- 最 高11.72
- 今 開11.61
- 成交量 227.95万股
- 最 低 11.02
- 昨 收 11.65
- 總市值 8.74亿
- 52周最高 17.43
- 市盈率 靜 --
- 換手率 2.92%
- 52周最低 5.60
- 委 比 93.71%
- 總股本 7805.87万
- 歷史最高 52.00
- 量 比 0.66
- 振 幅 6.01%
- 歷史最低 0.73
- 每 手 1
- 風險率 1.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Beyond The Numbers: 4 Analysts Discuss Cormedix Stock
Cormedix (NASDAQ:CRMD) underwent analysis by 4 analysts in the last quarter, re...
10-22 06:01
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
D. Boral Capital Upgrades Cormedix to Buy, Announces $14 Price Target
D. Boral Capital analyst Jason Kolbert upgrades Cormedix (NASDAQ:CRMD) from Hold to Buy and announces $14 price target.
10-20 21:33
Market-Moving News for October 20th
REPL: 81% | The FDA Accepts Replimune's Resubmission Of The Biologics License Application For RP1 In Combination With Nivolumab For Advanced Melanoma, PDUFA Date Is April 10, 2026 DVLT: 20% | Datavault AI
10-20 19:36
CorMedix shares are trading higher after the company raised its 2025 pro forma net revenue guidance.
CorMedix shares are trading higher after the company raised its 2025 pro forma ...
10-20 19:33
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
CorMedix Inc. reported Q3 2025 unaudited pro forma net revenue of over $125 million, including $85 million for DefenCath, and raised its FY 2025 pro forma net revenue guidance to at least $375 million, up from $325-$350 million. The company expects Q3 2025 adjusted EBITDA of at least $70 million and forecasts $30 million in operating synergies by year-end 2025. CorMedix has completed enrollment in the Phase III ReSPECT study for Rezzayo, with cli...
10-20 11:30
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
CorMedix Inc. announced the completion of enrollment for its Phase III ReSPECT trial evaluating the efficacy of REZZAYO® (rezafungin) in preventing fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. Sponsored by Mundipharma, the trial aims to assess once-weekly rezafungin against a standard antimicrobial regimen. Topline results are expected in Q2 2026. REZZAYO is approved in the U.S. for treating candidem...
09-29 12:30
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Analyst Expectations For Cormedix's Future
During the last three months, 6 analysts shared their evaluations of Cormedix (...
09-10 02:01
